Structure of Proline- and Arginine-Rich Peptides that Lead to Inhibition of Inflammation and Induction of Angiogenesis


The Technology: PR39, a naturally produced proline-and-arginine-rich peptide consisting of 39 amino acids, induces angiogenesis and reduces inflammation in mouse models. Through structural and biochemical investigations of PR11, a truncated form of PR39, researchers at the University of Texas Health Science Center at Houston (UTHSC-H) have identified that the 20S proteasome-inhibiting activity of PR39 depends on specific amino acids and structural characteristics. They have also discovered a novel 12-amino acid peptide that has comparable activity as PR39.

The linear amino acid sequence does not allow the development or design of non-proteinaceous, small molecules, drugs based on the PR-peptides. With the identification of the structural properties required for the biological activity of PR11, pharmacophore information is now available for structure-based drug development and design. This peptide and its mutants are potential drugs for the treatment of heart diseases, inflammation, and stroke, as well as help establish a model system for cancer.

References: J Mol Biol. 2008 Dec 5; 384(1):219-27.

UTHealth Ref. No.: 2006-0014

Inventors:  Veeraraghavan et al

Patent Status:  U.S. Patent No.8,030,446

License Available:  world-wide; non-exclusive, exclusive


Patent Information:

The preceding is intended to be a non-confidential and limited description of a novel technology created at the University of Texas Health Science Center at Houston (UTHealth). This promotional material is not comprehensive in scope and should not replace company’s diligence in a thorough evaluation of the technology. Please contact the Office of Technology Management for more information regarding this technology.
For Information, Contact:
Danielle Martinez
Technology Licensing Associate
University of Texas Health Science Center At Houston
© 2022. All Rights Reserved. Powered by Inteum